JP2024537178A5 - - Google Patents

Info

Publication number
JP2024537178A5
JP2024537178A5 JP2024520883A JP2024520883A JP2024537178A5 JP 2024537178 A5 JP2024537178 A5 JP 2024537178A5 JP 2024520883 A JP2024520883 A JP 2024520883A JP 2024520883 A JP2024520883 A JP 2024520883A JP 2024537178 A5 JP2024537178 A5 JP 2024537178A5
Authority
JP
Japan
Prior art keywords
malignant neoplasms
fusion protein
cancer
protein according
neoplasms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537178A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077779 external-priority patent/WO2023060248A1/en
Publication of JP2024537178A publication Critical patent/JP2024537178A/ja
Publication of JP2024537178A5 publication Critical patent/JP2024537178A5/ja
Pending legal-status Critical Current

Links

JP2024520883A 2021-10-08 2022-10-07 p53媒介性癌の処置のための組成物および方法 Pending JP2024537178A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163253759P 2021-10-08 2021-10-08
US63/253,759 2021-10-08
PCT/US2022/077779 WO2023060248A1 (en) 2021-10-08 2022-10-07 Compositions and methods for the treatment of p53-mediated cancers

Publications (2)

Publication Number Publication Date
JP2024537178A JP2024537178A (ja) 2024-10-10
JP2024537178A5 true JP2024537178A5 (cg-RX-API-DMAC7.html) 2025-10-14

Family

ID=83995572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520883A Pending JP2024537178A (ja) 2021-10-08 2022-10-07 p53媒介性癌の処置のための組成物および方法

Country Status (6)

Country Link
US (1) US20240400626A1 (cg-RX-API-DMAC7.html)
EP (1) EP4413023A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024537178A (cg-RX-API-DMAC7.html)
CN (1) CN118488962A (cg-RX-API-DMAC7.html)
CA (1) CA3234720A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023060248A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119684450B (zh) * 2024-12-25 2025-08-05 无锡傲锐东源生物科技有限公司 抗人bcor蛋白单克隆抗体及其杂交瘤细胞株和应用
CN120966914B (zh) * 2025-10-21 2025-12-23 曲阜师范大学 一种中华蜜蜂DnaJC28基因及其编码蛋白和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP1002119A1 (en) 1997-07-31 2000-05-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
US6630584B1 (en) * 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
GB0210746D0 (en) * 2002-05-10 2002-06-19 Medical Res Council Peptide
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US9169494B2 (en) 2010-01-12 2015-10-27 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
WO2011097456A2 (en) 2010-02-05 2011-08-11 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP2929045B1 (en) * 2012-12-05 2020-12-02 SOLA Biosciences LLC Protein expression enhancing polypeptides

Similar Documents

Publication Publication Date Title
Russell et al. Measles virus for cancer therapy
US10780096B2 (en) Pyrrolobenzodiazepine-antibody conjugates
ES2871001T3 (es) Conjugados de pirrolobenzodiazepinas y anticuerpos
JP2021506883A (ja) ピロロベンゾジアゼピン抗体結合体
EA020324B1 (ru) АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
US20200197536A1 (en) Porous nanoparticle-supported lipid bilayer delivery of transcriptional gene modulators
JP2023089103A5 (cg-RX-API-DMAC7.html)
JP2025509290A (ja) Pcna阻害剤及びその使用
JP2022169780A5 (cg-RX-API-DMAC7.html)
WO2002039117A1 (en) Methods for the treatment of cellular proliferative disorders
Bulatova et al. Toward a topology-based therapeutic design of membrane proteins: Validation of NaPi2b topology in live ovarian cancer cells
WO2020211847A1 (zh) 替加色罗在制备抗肿瘤药物中的应用
JP2020521786A5 (cg-RX-API-DMAC7.html)
JP2011524355A5 (cg-RX-API-DMAC7.html)
Sanchez et al. Solitary extramedullary plasmacytoma of the head and neck: A report of three cases treated with curative radiotherapy and a review of the dose-control relationship
KR102495245B1 (ko) 피롤로벤조디아제핀-항체 컨쥬게이트
CN113677340A (zh) 作为抗癌药物的选择性且有效抑制Hakai介导的泛素化的化合物
CN117959423A (zh) 用于治疗和/或预防癌症的单克隆抗体及其相关产品
ElKashty Effectiveness of sulforaphane in increasing drug mediated cytotoxicity toward cancer stem cells in head and neck squamous cell carcinoma
US11597774B2 (en) Antibody variable domains and antibody constructs
WO2013157648A1 (ja) 医薬組成物
RASHEED et al. Solitary Extramedullary Plasmacytoma of the Thyroid Cartilage: A Case Report.
JP2007501259A (ja) 頭頸部がんの処置
ES2613031T3 (es) Compuestos antiproliferativos y su utilización
RU2718048C2 (ru) Противоопухолевое терапевтическое средство